Needham & Company LLC Reaffirms Hold Rating for ZimVie (NASDAQ:ZIMV)

ZimVie (NASDAQ:ZIMV)‘s stock had its “hold” rating restated by stock analysts at Needham & Company LLC in a report released on Thursday, MarketBeat.com reports.

ZimVie Stock Performance

ZIMV opened at $12.04 on Thursday. The firm has a market cap of $333.23 million, a P/E ratio of -0.92 and a beta of 2.10. ZimVie has a 1-year low of $11.62 and a 1-year high of $22.40. The company has a 50 day simple moving average of $13.50 and a two-hundred day simple moving average of $14.42. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.94 and a quick ratio of 1.38.

ZimVie (NASDAQ:ZIMV) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. ZimVie had a negative net margin of 77.31% and a positive return on equity of 2.90%. The business had revenue of $111.52 million during the quarter, compared to analyst estimates of $113.67 million. Equities analysts forecast that ZimVie will post 0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ZimVie

Several hedge funds and other institutional investors have recently made changes to their positions in ZIMV. Principal Financial Group Inc. bought a new position in shares of ZimVie in the third quarter worth about $275,000. Segall Bryant & Hamill LLC bought a new position in ZimVie during the 3rd quarter worth about $891,000. Dynamic Technology Lab Private Ltd bought a new position in ZimVie during the 3rd quarter worth about $470,000. Jacobs Levy Equity Management Inc. grew its holdings in ZimVie by 1.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 398,306 shares of the company’s stock worth $6,321,000 after acquiring an additional 6,235 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in ZimVie during the 3rd quarter worth about $528,000. Hedge funds and other institutional investors own 95.63% of the company’s stock.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.